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1. Introduction
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting
from defects of insulin action, insulin secretion or both [1]. Diabetes has taken place as one of the
most important diseases worldwide, reaching epidemic proportions. Global estimates predict
that the proportion of adult population with diabetes will increase 69% for the year 2030 [2].
Hyperglycemia in the course of diabetes usually leads to the development of microvascular
complications, and diabetic patients are more prone to accelerated atherosclerotic macrovas‐
cular disease. These complications account for premature mortality and most of the social
and economical burden in the long term of diabetes [3].
Increasing evidence suggests that oxidative stress plays a role in the pathogenesis of diabe‐
tes mellitus and its complications [4]. Hyperglycemia increases oxidative stress, which con‐
tributes to the impairment of the main processes that fail during diabetes, insulin action and
insulin secretion. In addition, antioxidant mechanisms are diminished in diabetic patients,
which may further augment oxidative stress [5, 6]. Several studies have addressed the possi‐
ble participation of dietary antioxidants, such as vitamins, in ameliorating the diabetic state
and retarding the development of diabetes complications [7, 8].
The aim of this chapter is to revise the current knowledge of the role of oxidative stress in
the pathogenesis of diabetes mellitus and its complications, and to discuss the existing evi‐
dence of the effects of vitamins as antioxidant therapy for this disease.
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2. Oxidative stress
At the beginning of life, the organisms obtained their energy (ATP) by anoxygenic photosin‐
thesis, for which oxygen was toxic. Most of the metabolic pathways were developed during
this anaerobic stage of life, in which oxygen came later. Cyanobacteria started producing
oxygen from photosynthesis, which raised the atmospheric oxygen, and favored those or‐
ganisms which have evolved into eukaryotic cells with mitochondria, able to use oxygen for
a more efficient energy production [9].
Whenever a cell’s internal environment is perturbed by infections, disease, toxins or nutri‐
tional imbalance, mitochondria diverts electron flow away from itself, forming reactive oxy‐
gen species (ROS) and reactive nitrogen species (RNS), thus lowering oxygen consumption.
This “oxidative shielding” acts as a defense mechanism for either decreasing cellular uptake
of toxic pathogens or chemicals from the environment, or to kill the cell by apoptosis and
thus avoid the spreading to neighboring cells [9]. Therefore, ROS formation is a physiologi‐
cal response to stress.
The term “oxidative stress” has been used to define a state in which ROS and RNS reach
excessive levels, either by excess production or insufficient removal. Being highly reactive
molecules, the pathological consequence of ROS and RNS excess is damage to proteins, lip‐
ids and DNA [10]. Consistent with the primary role of ROS and RNS formation, this oxida‐
tive stress damage may lead to physiological dysfunction, cell death, pathologies such as
diabetes and cancer, and aging of the organism [11].
2.1. ROS and RNS production
ROS and RNS are highly reactive molecules, which can be free radicals such as superoxide
(•O2 -), hydroxyl (•OH), peroxyl (•RO2), hydroperoxyl (•HRO2 -), nitric oxide (•NO) and nitro‐
gen dioxide (•NO2 -), or nonradicals such as hydrogen peroxide (H2O2), hydrochlorous acid
(HOCl), peroxynitrite (ONOO-), nitrous oxide (HNO2), and alkyl peroxynitrates (RONOO).
Most of the studies regarding diabetes and its complications have addressed the role of su‐
peroxide (•O2 -), nitric oxide (•NO), and peroxynitrite (ONOO-) in this disease. There are ba‐
sically two pathways for •O2 - production: NADPH oxidases and mitochondrial function,
while •NO and ONOO- are produced by the Nitric Oxide Synthase pathway [10].
2.1.1. NADPH oxidases
Oxidases are enzymes which catalyze redox reactions involving molecular oxygen (O2). Su‐
peroxide is generated by oxidases via one-electron reduction of oxygen and the oxidation of
their substrates. Several oxidases exist in the body, such as xantine oxidase, glucose oxidase,
monoamine oxidase, cytochrome P450 oxidase, and NADPH oxidases.
NADP in the cell exists in its reduced (NADPH) and oxidized (NADP+) forms. NADPH
supplies reducing power in reactions for biosynthesis, and it also serves as electron donor
substrate for the NADPH oxidase. This enzyme is a membrane-bound electron transport
complex which pumps electrons from NADPH in the cytosol across biological membranes
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and into intracellular and extracellular compartments, such as nucleus, endoplasmic reticu‐
lum, endosome, phagosome, mitochondria and extracellular space. It is the only enzyme
whose primary function is generating superoxide and/or hydrogen peroxide, mainly for
preventing the transfer of pathogens and for cellular bactericidal function[12, 13].
2.1.2. Mitochondrial electron transport chain
Mitochondrion is the site of eukaryotic oxidative metabolism. It contains the enzymes need‐
ed for converting pyruvate into Acetyl-CoA, the citric acid cycle (also known as the Krebs
cycle) and for fatty acid oxidation. Additionally, it performs the electron transport and oxi‐
dative phosphorylation. Substrate (amino acid, fatty acid and carbohydrate) oxidation in the
citric acid cycle release electrons, which are transferred to the coenzymes NAD+ and FAD to
form NADH and FADH2. These electrons then pass into the mitochondrial electron-trans‐
port chain, a system of linked electron carrier proteins comprised by Complexes I, II, III and
IV. Complex I, III, and IV drive the exit of protons from the mitochondrial matrix, producing
a proton gradient across the inner mitochondrial membrane. The free energy stored in this
electrochemical gradient drives the condensation of ADP with inorganic phosphate in order
to form ATP by oxidative phosphorylation. Along this electron transport, molecular oxygen
is the final electron acceptor, which will be then reduced to H2O [14, 15]. However, between
0.4 and 4% of all oxygen consumed will be converted into superoxide anion [16]. There is
also a normal threshold for protonic potential above which electron transfer is inhibited at
complex III, causing the electrons to go back to complex II where there are transferred to
molecular oxygen prematurely and not to complex IV as it naturally occurs. Therefore, the
endproduct of this transfer is superoxide [17].
Mitochondria play an important role in the maintenance of cellular redox status, acting as a
redox sink and limiting NADPH oxidase activity. However, when the proton potential
threshold is surpassed, mitochondria is also a significant source of ROS, which may further
stimulate NADPH oxidases, creating a vicious cycle of ROS production [18]. When mito‐
chondria cannot further extract oxygen, cell and tissue oxygen levels rise, decreasing the tis‐
sue extraction of oxygen from the blood. This results in tissue vascularity reduction, which
may be associated with peripheral vascular disease and, in time, chronic tissue hypoxia and
ischemia [9].
2.1.3. NO and RNS production
Nitric oxide •NO is produced by the enzyme nitric oxide synthase (NOS), of which there are
three isoforms: neural (nNOS or NOS-I) expressed in neurons, inducible (iNOS or NOS-II)
expressed in smooth muscle of bold vessels, hepatocites, macrophagues and neuroendocirne
tissue, and endothelial (eNOS or NOS-III) expressed constitutively in endothelial cells. iNOS
and eNOS can be stimulated by the redox state in the cell, cytokines, hormones and nu‐
trients [19, 20]. NOS catalyze the oxidation of the terminal guanidine nitrogen of the L–argi‐
nine, in presence of oxygen and NADPH, to yield L-citruline and •NO [21].
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Once produced and released, •NO can diffuse freely through membranes or act on different
cellular targets. •NO participates as mediator of several physiological effects such as vasore‐
laxation, macrophague activation, gene expression and apoptosis. Usually, •NO is consid‐
ered as a vasculoprotective molecule. However, one of its multiple effects is also protein
nitrosilation at the thiol groups and RNS generation such as peroxynitrite (ONOO-), as •NO
easily reacts with •O2 -. Therefore, the amount of •O2 - determines whether •NO acts as a pro‐tective or harmful molecule [10, 22].
2.2. Antioxidant defenses in the organism
As a small part the oxygen consumed for aerobic processes will be converted into superox‐
ide anion [16], which will have to be scavenged or converted into less reactive (and harmful)
molecules. The main enzymes that regulate this process are Superoxide dismutase (SOD),
Glutathione Peroxidase (GSH-Px) and Catalase (Figure 1). When ROS overproduction or
chronic hyperglycemia occurs, the activity of these enzymes is insufficient, leading to more
ROS and RNS formation and activation oxidative stress pathways.
Figure 1. Antioxidant defenses in the organism.
SOD is considered a first-line defense against ROS. This enzyme is present in nearly all cells,
and converts •O2 - into H2O2. Mitochondrial and bacterial SOD contain Mn, while cytosolicSOD is a dimer containing Cu and Zn. As the H2O2 may still react with other ROS, it needs tobe degraded by either one of the other two antioxidant enzymes, GSH-Px or catalase [10, 12].
GSH peroxidase is located in the mitochondria. It catalyzes degradation of H2O2 by reduc‐tion, where two gluthathione (GSH) molecules are oxidized to glutathione disulfide (GSSG).
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Regeneration of GSH by GSH-reductase, requires NADPH, which is oxidized to NADP+.
Catalase, on the other hand, is localized primarily in peroxisomes, and so it detoxifies the
H2O2 that diffuses from the mitochondria to the cytosol, converting it into water and molec‐
ular oxygen [10, 12].
There are also nonenzymatic antioxidant mechanisms, which mostly help regenerate GSSG
back into GSH. Antioxidant vitamins such as A, C, E and alpha-lipoic acid are among these
mechanisms. Although all these antioxidant defenses work together to eliminate H2O2 (and
thus superoxide) from the cell, in the presence of reduced transition metals (Cu, Fe), H2O2
can be transformed into •OH, which is a highly reactive ROS, by the Fenton reaction [10, 23].
2.3. Metabolic and signaling pathways involved in oxidative stress in diabetes
There are several molecular pathways involved in ROS formation and ROS induced dam‐
age. Here we will review the ones that have been related to oxidative stress in diabetes. Not
surprisingly, most of them are related to glucose and/or lipid metabolism.
2.3.1. Glucose oxidation and GAPDH
In order to generate energy, glucose needs to be first oxidized inside the cells by glycolysis.
In this process, once glucose enters the cells, it is phosphorylated to form glucose-6-phos‐
phate, a reaction mediated by hexocinases. Glucose-6-P is then converted to Fructose-6-P by
phosphoglucoisomerase, which can undergo two fates: the pentose phosphate pathway,
where reduction of NADP+ to NADPH occurs, or to continue glycolysis to yield Gliceralde‐
hyde-3-P. Glyceraldehyde-3-P dehydrogenase (GAPDH) phosphorylates this product and
glycolysis is further completed until its end product pyruvate, which enters the Krebs cycle
and mitochondrial metabolism (Figure 2).
It  has  been  proposed  that  hyperglycemia-induced  mitochondrial  superoxide  production
activates  damaging  pathways  by  inhibiting  glyderaldehyde-3-phosphate  dehydrogenase
(GAPDH)  [4,  24],  an  enzyme that  normally  translocates  in  and  out  of  the  nucleus  [25,
26]. ROS inhibit glyderaldehyde-3-phosphate dehydrogenase through a mechanism involv‐
ing  the  activation  of  enzyme  poly-ADP-ribose  polymerase-1  (PARP-1).  This  enzyme  is
involved  in  DNA  repair  and  apoptotic  pathways.  ROS  cause  strand  breaks  in  nuclear
DNA which activates PARP-1. PARP-1 activation results in inhibition of glyderaldehyde-3-
phosphate dehydrogenase by poly-ADP-ribosylation [27].  This results in increased levels
of  all  the  glycolytic  intermediates  upstream  of  GAPDH.  Accumulation  of  glyceralde‐
hyde  3-phosphate  activates  two  major  pathways  involved  in  hyperglycemia-complica‐
tions: a) It activates the AGE pathway deriving glyceraldehyde phosphate and dihydroxyacetone
phosphate  to  the  nonenzymatic  synthesis  of  methylglyoxal.  b)  Increased glyceraldehyde
3-phosphate favors diacylglycerol production which activates PKC pathway. Further up‐
stream, levels of the glycolytic metabolite fructose 6-phosphate increase, which then increas‐
es flux through the hexosamine pathway, where fructose 6-phosphate is converted by the
enzyme glutamine-fructose-6-phosphate amidotransferase (GFAT) to UDP–N-Acetylglucos‐
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amine. Finally, inhibition of GAPDH favors the accumulation of the first glycolytic metab‐
olite, glucose. This increases its flux through the polyol pathway, consuming NADPH in
the process [24].
2.3.2. The polyol pathway
The family of aldo-keto reductase enzymes catalyzes the reduction of a wide variety of car‐
bonyl compounds to their respective alcohols. These reactions utilize nicotinic acid adenine
dinucleotide phosphate (NADPH). Aldo-keto reductase has a low affinity (high Km) for glu‐
cose, and at the normal glucose concentrations, metabolism of glucose by this pathway is a
very small percentage of total glucose metabolism. However, in a hyperglycemic environ‐
ment, increased intracellular glucose results in its increased enzymatic conversion to the
polyalcohol sorbitol, with concomitant decreases in NADPH [4] (Figure 2). Since NADPH is
a cofactor required to regenerate reduced glutathione, an antioxidant mechanism, and this
compound is an important scavenger of reactive oxygen species (ROS), this could induce or
exacerbate intracellular oxidative stress [24]. Moreover, sorbitol is oxidated to fructose by
sorbitol dehydrogenase, which can lead to PKC activation via the increased NADH/NAD+
ratio [4]. Although this mechanism does not produce ROS in a direct way, it takes part in the
redox imbalance causing oxidative stress.
2.3.3. Hexosamine pathway
When glucose levels are within normal range, a relatively low amount of fructose-6-P is
drived away from glycolysis. If intracellular glucose rises, excess fructose-6-phosphate is di‐
verted from glycolysis to provide substrate for the rate-limiting enzyme of this pathway,
GFAT. This enzyme converts fructose 6-phosphate to glucosamine 6-phosphate, which is
then converted to UDP-NAcetylglucosamine, which is essential for making the glycosyl
chains of proteins and lipids. Specific O-Glucosamine-N-Acetyl transferases use this metab‐
olite for post-translational modification of specific serine and threonine residues on cyto‐
plasmic and nuclear proteins [24, 28].
2.3.4. Diacylglycerol formation and PKC activation
The Protein Kinase C (PKC) family comprises at least eleven isoforms of serine/threonine
kinases, which participate in signaling pathways activated by phosphatidyl serine, Calci‐
um and Diacylglycerol (DAG). DAG levels are elevated chronically in the hyperglycemic
or diabetic  environment due to an increase in the glycolytic  intermediate dihydroxyace‐
tone  phosphate  (figure  2).  This  intermediate  is  reduced  to  glycerol-3-phosphate,  which,
conjugated with fatty acids, increases de novo synthesis of DAG [29].  Evidence suggests
that  the enhanced activity of  PKC isoforms could arise from inhibition of  the glycolytic
enzyme glyceraldehide-3-phosphate dehydrogenase by increased ROS intracellular levels
[4, 24]. Other studies suggest that enhanced activity of PKC isoforms could also result from
the interaction between AGEs and their extracellular receptors [30]. PKC isoforms consti‐
tute a wide range of cellular signals, including activation of NADPH oxidase and NF-κB,
resulting in excessive ROS production. They also increase vascular permeability, stabilize
Oxidative Stress and Chronic Degenerative Diseases - A Role for Antioxidants214
vascular endothelial growth factor (VEGF) mRNA expression and increase leukocyte-endo‐
thelium interaction [11].
2.3.5. Glyceraldehyde autoxidation
Accumulation of glyceraldehyde 3-phosphate, besides activating the AGE formation and the
PKC pathway, it can oxidate itself. This autoxidation generates H2O2, which further contrib‐
utes to oxidative stress [31].
2.3.6. Advanced glycation end-products (AGEs)
Intracellular hyperglycaemia is the primary initiating event in the formation of both intracel‐
lular and extracellular AGEs [32]. AGEs can arise from intracellular auto-oxidation of glu‐
cose to glyoxal, decomposition of the Amadori product (glucose-derived 1-amino-1-
deoxyfructose lysine adducts) to 3-deoxyglucosone (perhaps accelerated by an amadoriase),
and nonenzymatic phosphate elimination from glyceraldehyde phosphate and dihydroxya‐
cetone phosphate to form methylglyoxal. These reactive intracellular dicarbonyl glyoxal,
methylglyoxal and 3-deoxyglucosone react with amino groups of intracellular and extracel‐
lular proteins to form AGEs [4]. Intracellular production of AGE precursors can damage
cells by three general mechanisms: 1) Intracellular proteins modified by AGEs have altered
function, 2) Extracellular matrix components modified by AGE precursors interact abnor‐
mally with other matrix components and with matrix receptors (integrins) that are ex‐
pressed on the surface of cells, and 3) Plasma proteins modified by AGE precursors bind to
AGE receptors (such as RAGE and AGE-R1,2 and 3) on cells such as macrophages, vascular
endothelial cells and vascular smooth muscle cells. AGE receptors binding induces the pro‐
duction of ROS, which in turn activates PKC. It also activates NF-κB and NADPH oxidase,
and disturbs MAPK signaling [31].
2.3.7. Stress-sensitive signaling pathways
In addition to direct damage of biomolecules in the cells, oxidative stress is also involved
in activation of several stress-sensitive signaling pathways, which can result in inflamma‐
tion, cytokine release, and even apoptosis. Among these pathways we find the transcrip‐
tion  factor  NF-κB,  which  together  with  PARP  acts  as  a  transcriptional  coactivator  of
inflammation  molecules  such  as  iNOS,  intracellular  adhesion  molecule-1  (ICAM-I),  and
histocompatibility complex class II [33]. p38 MAPK pathway and c-Jun Nterminal kinase
(JNK) (also known as stress-activated protein kinase (SAPK) participate in cellular respons‐
es to stress due to osmotic shock, cytokines and UV light, playing a role in cellular prolif‐
eration, apoptosis, and inflammatory responses [33]. Jak/STAT is another important signaling
pathway, which initiates and mediates cellular responses to cytokines such as interferons
and interleukins [33].
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Figure 2. Oxidative stress-related pathways derived from glucose metabolism.
2.4. ROS induced damages
Being highly reactive species, ROS may modify and damage nucleic acids, proteins, lipids
and carbohydrates, finally leading to cell damage. Among the motifs that can react with
ROS we have the metal ligand from metalloproteases and Fe from oxihemoglobin. •O2 - can
also modify and inhibit catalases, while •OH can bind to the histidine residue from SOS
causing its inhibition. ROS react mostly with insaturated and sulfur containing molecules,
thus, proteins with high contents of tryptophan, tyrosine, phenylalanine, histidine, methio‐
nine and cysteine can suffer ROS modifications. Finally, ROS may also break peptidic bonds
after oxidation of proline residues by •O2 - or •OH [31].
ROS and RNS may also modify fatty acids, lipoproteins, and phospholipids, a process
termed lipid peroxidation, where •OH and •O2 - form hydroperoxide lipids. Hydroperoxyde
products cause severe damage to plasma membranes, or they can diffuse to other cells in the
organisms and cause vascular permeability and inflammation by binding to (oxidized low-
density lipoprotein) LOX receptors, and apoptosis [31].
H2O2 in cells can function as a signaling molecule leading to cellular proliferation or can re‐
sult in cell death. At low concentrations, H2O2 serves as a second messenger to activate NF-
κB and various kinases (p38 MAPK, ERK, PI3K, Akt, JAK2, STAT). H2O2 at slightly higher
concentrations can induce the release of cytochrome c and apoptosis-inducing factor (AIF)
from mitochondria into the cytosol where they trigger the activation of caspase, leading to
cell death by apoptosis [12].
Oxidative Stress and Chronic Degenerative Diseases - A Role for Antioxidants216
3. Diabetes mellitus
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia, caused
by a defect on insulin production, insulin action or both [1]. There are two main types of dia‐
betes: type 1 and type 2 diabetes.
Type 1 diabetes is due to an autoimmune destruction of the insulin producing pancreatic beta-
cells, which usually leads to absolute insulin deficiency. Patients with type 1 diabetes re‐
quire insulin for survival. This type of diabetes accounts for 5-10% of the total cases of diabetes
worldwide. Type 2 diabetes represents approximately 90% of the total diabetes cases, and it
is characterized by impairment in insulin action and/or abnormal insulin secretion [1].
The origins of type 2 diabetes are multifactorial. Obesity, age, ethnic origin and familiar his‐
tory of diabetes are among the factors that contribute to its development. Even though a
strong genetic component has been recognized, genotype only establishes the conditions for
the individual to be more or less prone to environmental effects and lifestyle factors [34].
Type 2 diabetes develops when insulin secretion or insulin action fails. The impairment of
insulin actions is known as insulin resistance, presented as a suppression or retard in meta‐
bolic responses of the muscle, liver and adipose tissue to insulin action. This failure is locat‐
ed at the signaling pathways held after insulin binding to its specific receptor [35]. Chronic
insulin resistance leads to hyperglycemia.
When the beta cells cannot secrete enough insulin in response to the metabolic demand caused
by insulin resistance, frank diabetes type 2 occurs. This failure in the beta cell may be due to
an acquired secretory dysfunction and/or a decrease in beta-cell mass [36]. All type 2 diabet‐
ic patients have some defect in the ability of beta cells to produce or secrete insulin [37].
3.1. Insulin action and insulin resistance
Once secreted to the portal circulation, insulin is transported to peripheral tissues, on which
it will exert mainly anabolic actions [38]. Insulin starts its action by binding to insulin recep‐
tor, a transmembrane protein belonging to protein tyrosine kinase activity receptors super‐
family, which can autophosphorylate. This initiates a series of events involving protein and
membrane lipid phosphorylation, coupling proteins and cytoskeleton activity [39] [40]. The
three main signaling pathways activated in response to insulin receptor phosphorylation are
1) PI3K 2)MAPK, and 3) Cb1. These pathways act in a concerted way to translate the signal
of insulin receptor into biological actions in target organs, such as glucose transport by
transporting GLUT4 vesicles to the membrane, protein, lipid and glycogen synthesis, mito‐
sis and gene expression [40] (Figure 3).
As protein phosphorylation activates these signaling pathways, dephosphorylation inhibits
them. Different phosphatases such as protein-tyrosine phosphatase 1B (PTP1B), Phospha‐
tase and tensin homolog (PTEN), SH2-containing tyrosine- protein phosphatase (SHO2),
and suppressor of cytokine signaling 3 (SOCS-3) dephosphorylate and shut down insulin
signaling [35]. Any alteration in the insulin pathway, being inefficient phosphorylation or
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increment in phosphatase acticity, causes impairment in insulin action. This is the molecular
mechanism leading to insulin resistance.
Figure 3. Molecular mechanisms of insulin signaling.
3.2. Insulin secretion
Beta-cells in the endocrine pancreas are responsible for secreting insulin in response to rises
in blood nutrient levels during the postprandial state. Glucose is the most important nu‐
trient for insulin secretion. The process by which glucose promotes insulin secretion re‐
quires glucose sensing and metabolism by the beta-cell, a process called glucose-stimulated
insulin secretion (Figure 4). In the first phase of insulin secretion, glucose enters the cell by
glucose transporters (GLUT2 in rodents, GLUT1 in humans). Glucose is then phosphorylat‐
ed to form glucose-6-phosphate by glucokinase [41]. The generation of ATP by glycolysis,
the Krebs cycle and the respiratory chain closes the ATP-sensitive K+ channel (KATP) [42],
allowing sodium (Na+) entry without balance. These two events depolarize the membrane
and open voltage-dependent T-type calcium (Ca2+) and sodium (Na+) channels. Na+ and
Ca2+ entry further depolarizes the membrane and voltage-dependent calcium channels
open. This activation increases intracellular Ca2+ ([Ca2+]i) [43], which leads to fusion of in‐
sulin-containing secretory granules with the plasma membrane and the first phase insulin
secretion [44, 45].
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Figure 4. Mechanisms of biphasic glucose-stimulated insulin secretion.
Besides increasing ATP/ADP ratio, glucose metabolism in the beta cell can generate a series
of metabolic coupling signals that can initiate and sustain a second insulin secretion phase.
Some of these coupling factors participate in mitocondrial metabolism and anaplerosis, con‐
stituting cycles involving NADPH, pyruvate, malate, citrate, isocitrate, Acyl-CoA and gluta‐
mate [46]. Diverse signaling pathways can also contribute to glucose-induced insulin
secretion such as CaMKII [47-49], PKA [50, 51], PKC [51, 52] y PKG [53, 54]. Most secretago‐
gues and potentiators of insulin secretion, such as nutrients, hormones and neurotransmit‐
ters, use these pathways to modulate insulin secretion.
4. Oxidative stress in diabetes mellitus
Hyperglycemia and free fatty acid intake are among the causes for oxidative stress condi‐
tions [23]. Hence, it may not be surprising that diabetic subjects tend to have more oxidative
cell and organism environments than healthy subjects, i.e. an increase in ROS generation [5,
55, 56]. Moreover, diabetic patients present a decrease in antioxidant defenses. The antioxi‐
dant enzyme levels are affected by diabetes, which further increase oxidative stress [5, 6].
Oxidative stress has been proposed as a major participant in the patophysiology of diabetic
complications [27]. Nevertheless, regarding diabetes onset and development, oxidative
stress has also shown to affect the two major mechanisms failing during diabetes: insulin re‐
sistance and insulin secretion.
4.1. Oxidative stress processes in insulin resistance
ROS and RNS affect the insulin signaling cascade [5]. As with other ROS effects, low doses
play a physiological role in insulin signaling. After insulin stimulation of its receptor in adi‐
pocytes, H2O2 is produced via NADPH oxidase, which by inhibits PTP1B catalytic activity,
thus increasing tyrosine phosphorylation [57].
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However, oxidative stress caused by hyperglycemia in diabetes may impair insulin signal‐
ing, leading to insulin resistance. Although no mechanisms have been completely establish‐
ed, several responses to ROS excess in the insulin signaling have been proposed.
Disturbs in cellular redistribution of insulin signaling components may alter the insulin cas‐
cade, a process mediated by NF-κB [58]. A decrease in GLUT4 gene transcription and in‐
crease in GLUT1 (insulin independent glucose transporter) has also been observed, as well
as increases in phosphorylation of IRS protein in an insulin receptor-independent fashion
(perhaps by the stress kinases). Altogether, hyperglycemia and insulin resistance may also
lead to altered mitochondrial function, and insulin action impairment by cytokines in re‐
sponse to metabolic stress [59, 60]. An increase in the hexosamine pathway has also been
linked to insulin resistance. Moreover, it has been proposed that this pathway acts as a cellu‐
lar sensor for the glucose excess. From that point of view, insulin resistance may be a protec‐
tive mechanism from the glucose excess entrance [28].
4.2. Oxidative stress processes in insulin secretion
Pancreatic beta-cells are especially sensitive to ROS and RNS, because their natural enzymat‐
ic antioxidant defenses are lower compared to other tissues such as liver. Moreover, they lack
the ability to adapt their low enzyme activity levels in response to stress such as high glu‐
cose or high oxygen [61]. Glucose enters to the beta-cell in an insulin independent fashion,
because besides providing energy, glucose sensing in the beta-cell is crucial for insulin secre‐
tion. It has been suggested that hyperglycemia can generate chronic oxidative stress by the
glucose oxidation pathway [62], leading to an excess in mitochondrial superoxide produc‐
tion, which further activates uncoupling protein-2 (UCP-2). This protein lowers ATP/ADP
relationship through proton leak in the beta-cell, which reduces insulin secretion [63].
ROS also increase the stress signaling pathways in the beta cells, such as NF-κB activity,
which potentially leading to beta-cell apoptosis [64], and the JNK pathway which has been
related to suppression of insulin gene expression, possibly by reduction of PDX-1 DNA
binding activity, a major regulator of insulin expression [65]. It has also been shown that the
activation of the hexosamine pathway in beta-cells leads to suppression of PDX-1 binding to
the insulin and other genes involved in insulin secretion, perhaps contributing to the beta-
cell dysfunction present in diabetes mellitus [66].
As in other cell types, NO in beta-cells has physiologic roles. NO may regulate glucokinase
activity by s-nitrosilation [67] in the beta-cell, and possibly increase insulin secretion. How‐
ever, NO excess and concomitant NRS may cause apoptosis through caspase-3 activation
and decrease in ATP levels [68].
Besides ROS hyperproduction, excess mitochondrial metabolism resulting form hypergly‐
cemia in the beta-cell  may also alter mitochondrial  shape, volume and behavior,  uncou‐
pling  K-ATP  channels  from  mitochondrial  activity  and  thus  altering  glucose-induced
insulin secretion [69].
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5. Diabetic complications
Hyperglycemia, is the responsible of the development of diabetes complications as well. Hy‐
perglycemia damage is produced in cells in which glucose uptake is independent of insulin,
which, similarly to what happens in beta-cells, explains that the cause of the complications
resides inside the cells [4]. Prolonged exposure to high glucose levels, genetic determinants
of susceptibility and accelerating factors such as hypertension and dyslipidemia participate
in the development of diabetic complications. Moreover, the development and progression
of damage is proportional to hyperglycemia, which makes the lowering of glucose levels the
most important goal for preventing complications and treating diabetes.
The main tissues affected by diabetes complications at the microvasculature levels are reti‐
na, renal glomerulus, and peripheral nerves. Diabetes is also associated with accelerated
atherosclerotic disease affecting arteries that supply the heart, brain, and lower extremities.
In addition, diabetic cardiomyopathy is a major diabetic complication [24].
5.1. Oxidative stress in diabetic complications
Oxidative stress plays a pivotal role in the development of diabetes complications, both at
the microvascular and macrovascular levels. Results derived from two decades of diabetes
complications investigation point towards mitochondrial superoxide overproduction as the
main cause of metabolic abnormalities of diabetes. Thus, all of the above reviewed pathways
are involved in microvasculature and macrovasculature hyperglycemic damage [24].
5.2. Microvascular complications
Diabetic retinopathy: Diabetic retinopathy appears in most patients after 10 to 15 years after
diabetes onset. Background retinopathy presents small hemorrhages in the middle layers of
the retina, appearing as “dots”. Lipid deposition occurs at the margins of the hemorraghe,
and microaneurisms (small vascular dilatations) and edema may appear. Proliferative retin‐
opathy occurs when new blood vessels on the surface of the retina cause vitreous hemor‐
rhage, and eventually, blindness. As the cells of the retina contain high amounts of aldo-
ketoreductase, they have high susceptibility to increase the polyol pathway in the presence
of excess glucose, with concomitant decreases in NADPH [4]. Sorbitol produced in this proc‐
ess increases osmotic stress, which has been linked to microaneurysm formation, thickening
of the basement membranes and loss of pericytes. It is also thought that retina cells are dam‐
aged by glycoproteins, particularly form AGEs. Additionally, ROS by themselves may dam‐
age the cells. Importantly, VEGF, growth hormone and TGF-beta increases during diabetes
may be the cause of proliferation of blood vessels [70].
Diabetic nephropaty: this complication causes glomerular basement membrane thickness,
microaneurism formation, and mesangial nodule formation, all which are reflected in protei‐
nuria and, in the end, renal insufficiency. The mechanisms for injury also involve the in‐
creased polyol pathway and AGE formation. AGE binding to its receptors has been proven
to play a role as well in renal damage, fibrosis and inflammation associated with diabetic
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nephropaty. This actions of AGE also potentiate oxidative stress, while synergizing with
rennin-angiotensin system activation, which leads to a vicious cycle causing kidney failure.
As mentioned, diabetic patients, and particularly those with nephropaty, have lowered anti‐
oxidant defenses. Moreover, AGE receptors are significantly increased [71].
Diabetic neuropathy: Diabetic neuropathy is defined as the presence of symptoms and/or
signs of peripheral nerve dysfunction in diabetic patients after exclusion of other causes. Pe‐
ripheral neuropathy in diabetes may manifest in several different forms, including sensory,
focal/multifocal, and autonomic neuropathies. [72]. Mechanisms of nerve injury are less
known but likely related also to the polyol pathway, AGE formation and ROS themselves
[70]. Oxidized proteins and lipoproteins also interact with receptors in the membrane of
neurons, initiating inflammatory signaling mechanisms which further produce ROS, damag‐
ing cellular components and leading to neuronal injury [73].
5.3. Macrovascular complications
The central pathological mechanism in macrovascular complications is atherosclerotic dis‐
ease. Atherosclerosis occurs as a result of chronic inflammation and injury to the arterial
wall in the peripheral or coronary vascular system. This damages cause accumulation of oxi‐
dized lipids from LDL particles in the endothelial wall of arteries, whose rupture leads to
acute vascular infarction. Additionally, platelet adhesion and hypercoagulability also occurs
in type 2 diabetes, increasing the risk of vascular occlusion [70]. It has been proposed that
increased superoxide production is the central and major mediator of endothelial tissue
damage, causing direct inactivation of two antiatherosclerotic enzymes, endothelial nitric
oxide synthase and prostacyclin synthase and that the activation of oxidative stress path‐
ways is involved in the pathogenesis of complications [24].
Endothelial cells also contain high amounts of aldo-keto reductase, and are thus prone to in‐
creased polyol pathway activation. Moreover, a large body of evidence supports hypothesis
that hyperglycemia or diabetes leads to vascular diacylglycerol accumulation and subse‐
quent PKC activation, causing a variety of cardiovascular defects [29]. PKC activation has
been associated with vascular alterations such as increases in permeability, contractility, ex‐
tracellular matrix synthesis, cell growth and apoptosis, angiogenesis, leukocyte adhesion,
and cytokine activation and inhibition [29]. Hyperglycemia-induced activation of PKC has
also been implicated in the overexpression of the fibrinolytic inhibitor, plasminogen activa‐
tor inhibitor-1 (PAI-1) [74]. In smooth muscle PKC hyperactivity is associated with de‐
creased NO production [75] and has been shown to inhibit insulin-stimulated expression of
eNOs in endothelial cells.
In arterial endothelial cells O-glucosamine-acylation participates in vascular complications
interfering with the action of Akt/PKB, a critical insulin signaling protein, on eNOS [76].
GFAT activity is associated with increased transcription of transforming growth factor
(TGF) alpha and beta and PAI-1, factors involved in the proliferation of vascular smooth-
muscle and endothelial cells. This effect appears to be mediated by O-glucosamine-acylation
of the transcription factor, Sp1 [77]. Increased TGF-beta and PAI-1 are associated with capil‐
lary and vascular occlusion by mechanisms associated with collagen and fibronectin expres‐
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sion causing capillary occlusion, in the case of TGF-beta, and decreased fibrinolysis in the
case of PAI-1. O-GlcNAcylation impairs cardiomyocyte calcium cycling decreasing sarco‐
plasmic reticulum calcium ATPase 2a (Serca 2a) [78-80].
Figure 5. Oxidative stress pathways in diabetes mellitus.
6. Antioxidant vitamins and diabetes mellitus
As mentioned above, vitamins C, E, and A constitute the non enzymatic defense against
oxidative stress, by regenerating endogenous antioxidants (Figure 1). Vitamin C has a role
in scavenging ROS and RNS by becoming oxidated itself. The oxidized products of vita‐
min C, ascorbic radical and dehydroascorbic radical are regenerated by glutathione, NADH
or NADPH. In addition, vitamin C can reduce the oxidized forms of vitamin E and glutha‐
tione [81].  Vitamin E is a fat-soluble vitamin which may interact with lipid hydroperox‐
ides  and  scavenge  them.  It  also  participates,  together  with  vitamin  C,  in  gluthatione
regeneration by interaction with lipoic acid [23]. Vitamin A has a plethora of cellular ac‐
tions. Besides modulating gene expression, cell growth and differentiation, this vitamin may
also act as antioxidant, although the mechanisms of action in this role are not fully deci‐
phered. The antioxidant potential of carotenoids (vitamin A) depends on their distinct mem‐
brane-lipid interactions, while some carotenoids can decrease lipid peroxidation, others can
stimulate it [82].
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Since oxidative stress is present during the progression of diabetes and its complications,
amelioration of oxidative status, mainly by increasing antioxidant non-enzymatic defenses,
has been largely proposed and studied. Several clinical observational trials have particularly
studied the correlation between vitamin E status in plasma and/or diet, and markers of oxi‐
dation, inflammation, type 2 diabetes incidence, and diabetic complications. Although in‐
verse association has been found for vitamin E in some studies [7, 83, 84], the association
found in other study disappeared after adjustment for cardiovascular risk factors such as
obesity, smoking, and hypertension [85], or have observed no beneficial effect at all [7, 8].
Such contrasting results have also been reported for studies looking association of vitamin A
and C consumption and amelioration of diabetes status and/or complications [7, 8, 81, 86].
On the other hand, in interventional trials with vitamin supplementation, the effects of vita‐
mins E, C and A, alone or in diverse combinations, have yielded barely any promising re‐
sult. There appears to be no beneficial effect of vitamin supplementation on diabetes or
macrovascular complications [7, 8, 81]. Some of these studies have even evidenced associa‐
tions between vitamin supplementation and an increased incidence of stroke [7]. Likewise,
supplementation with antioxidant vitamins can even block beneficial ROS production dur‐
ing exercise, inhibiting the health-promoting effects of exercise in humans [87].
Paradoxically, in spite of the solid evidence of increased oxidative stress in diabetes, and the
well established actions of vitamins as antioxidants, the association studies between antioxi‐
dant vitamin status and its beneficial effects in diabetes has no consistent results at all. What
is more, interventional studies have failed in demonstrating a favorable effect of vitamin
supplementation, discouraging its use as antioxidant therapy for diabetes.
Several reasons have been suggested for these contradictory observations. First, as vitamins
may be easily oxidized, a vitamin may have antioxidant or oxidant properties, depending
on the presence of other vitamins and the oxidative state in the cells i.e., if the oxidized form
of a vitamin is not correctly reversed into the reduced form. Additionally, some vitamins
may also activate oxidative stress pathways and further increase the oxidative stress, such as
the activation of PKC by retinoids [88].
Vitamin doses may also be part of the problem, as the effect of vitamins depends on dietary
concentrations and/or supplement intake. The wide variety of doses reached with diet and
supplements, and the lack of an established “pharmacological” dose of vitamins, makes it
difficult to ascertain the true net effect of vitamin status or supplementation needed to gen‐
erate beneficial effects. As well, the required dose for antioxidant effects versus the required
for the vitamin’s role in the body may differ, which, together with vitamin’s bioavailability
and its interaction with other vitamins, are caveats for assessing and finding vitamins’ ef‐
fects, if any [7, 88].
Finally,  the  antioxidant  effects  of  vitamins  may  not  be  sufficient  to  scavenge  the  great
amount of ROS present in diabetes. Certainly, glucose levels have been correlated to the
presence and severity  of  the  complications.  However  once hyperglycemia has  establish‐
ed,  the  incidence  of  complications  after  tight  glycemic  control  remains  the  same.  This
effect has been termed glycemic memory, and is the cause for accumulative damage ren‐
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dering diabetic complications. Considering that hyperglycemia is the main cause of oxida‐
tive stress in diabetes, in a similar way, the chronic undesirable effects that occur by ROS
production may generate a vicious cycle difficult to break, in which ROS damage exacer‐
bates the diabetic state,  increasing glucose levels,  which will  further induce more oxida‐
tive imbalance [24].
7. Conclusions
Diabetes mellitus has reached epidemic proportions in the last decade, becoming one of the
most important diseases worldwide. Several studies indicate oxidative stress is present in
the dysfunction of insulin action and secretion that occur during diabetes, as well as in the
development of diabetic complications. Nevertheless, oxidative stress is not the primary
cause of diabetes, but rather a consequence of nutrient excess, given that oxidative stress is a
natural response to stress, in this case, to glucose and/or lipid overload.
Vitamins such as E, C and A with antioxidant properties constitute the physiological non-
enzymatic defense against oxidative stress. However, the evidence in favor of the use of vi‐
tamin supplementation as antioxidant therapy remains uncertain. Although some beneficial
effects have been proven in observational studies, the results of interventional trials are still
ineffective. Perhaps more studies on the physiopathology of oxidative stress and the role of
vitamins in it, as well as standardizing vitamin dosage and assessing their undesirable ef‐
fects are needed in order to determine a clear participation of vitamin supplementation in
amelioration of the oxidative balance. More studies addressing the possibility of targeting
directly at the enzymes and mechanisms involved in ROS production and not by antioxi‐
dants are needed as well.
Given that it is mostly dietary vitamin intake which has shown an association with amelio‐
rating the diabetic state, and that oxidative stress is a response to excess of nutrients, it
seems that attending the cause of excessive ROS production represents the best therapeutic
option. Thus, adequate dietary interventions that reduce hyperglycemia, and increases in
oxygen consumption (i.e. improve mitochondrial function) by exercise remain the primary
choices for diabetes treatment and prevention of its complications.
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